Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28658136 | 0.84 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL8610167 | 0.83 | ALDH1A1 (0.65) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL4279628 | 0.83 | ALDH1A1 (0.65) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL9740512 | 0.83 | ALDH1A1 (0.65) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL1562501 | 0.80 | ALDH1A1 (0.61) | ALDH1A1CYP1A2CYP2C9GAAMAPT | |
| SCHEMBL4268243 | 0.80 | KMT2A (0.60) | ALDH1A1CYP1A2CYP2C9GAAMAPT | |
| SCHEMBL13545621 | 0.79 | GAA (0.69) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL18262805 | 0.79 | GAA (0.59) | ALDH1A1CYP1A2CYP2C9GAACA12 | |
| SCHEMBL14697334 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP2C9GAAMAPT | |
| SCHEMBL4267439 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP2C9GAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | AMBRX,INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10800856-B2 | Prostate-specific membrane antigen antibody drug conjugates | AMBRX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3536700-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | Ambrx, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3470413-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | Ambrx, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2858676-B1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | AMBRX INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20060016752-A1 | Dialysis solution containing single compound with an antioxidant group, e.g., vitamin E, cinnamic acid derivatives, pyridoxamine, flavonoids, lipoic acid, linked to a carbonyl-trapping group, e.g., aminooxy or 1,2-aminothiol group via, e.g., piperazine, poly(ethylene glycol), or lysine; antiinflammatory | BAXTER INTERNATIONAL INC. | 2006-01-26 | — | — | US | disclosed |
| US-20050222243-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| EP-1539729-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NITROMED, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2004004648-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030125389-A1 | Beta-amino acid derivatives useful for the treatment of bacterial infections | VERSICOR, INC. | 2003-07-03 | — | — | US | disclosed |
| EP-0416814-A2 | Cephalosporin compounds, process for their preparation, pharmaceutical compositions and intermediates | BEECHAM GROUP PLC (GB) | 1991-03-13 | — | — | EP | disclosed |
| EP-0244637-A1 | Starting compounds for 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-11-11 | — | — | EP | disclosed |
| EP-0123024-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
| EP-0030630-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125389-A1 | Beta-amino acid derivatives useful for the treatment of bacterial infections | BCAT2, BCAT1, AADAT | ALDH1A1 1544/4885CYP1A2 1116/4885CYP2C9 862/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | ALDH1A1 868/4885CYP1A2 2119/4885CYP2C9 2579/4885 |
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NOS2, NOS1, NOS3 | ALDH1A1 383/4885CYP1A2 230/4885CYP2C9 109/4885 |
| US-10800856-B2 | Prostate-specific membrane antigen antibody drug conjugates | KLK3, PTMS, DDOST | ALDH1A1 2041/4885CYP1A2 3716/4885CYP2C9 3103/4885 |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DAD1, PTMS | ALDH1A1 4288/4885CYP1A2 4085/4885CYP2C9 1454/4885 |
| US-20050222243-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NOS2, NOS1, NOS3 | ALDH1A1 385/4885CYP1A2 229/4885CYP2C9 101/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | ALDH1A1 1177/4885CYP1A2 2172/4885CYP2C9 2597/4885 |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | KLK3, PTMS, DDOST | ALDH1A1 2041/4885CYP1A2 3716/4885CYP2C9 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.